Skip to main content
Review article

Mesenchymal stem cells and immunomodulation: current status and future prospects

Fei GaoDepartment of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongSheng‐Hao ChiuDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongDaniyal MotanDepartment of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongZ. ZhangDepartment of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongL. ChenDepartment of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongH-L JiDepartment of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler, Texas 75708, USAH-F TseDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong KongQ-L FuOtorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, ChinaQizhou LianDepartment of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
2016en
ABI

Abstract

The unique immunomodulatory properties of mesenchymal stem cells (MSCs) make them an invaluable cell type for the repair of tissue/ organ damage caused by chronic inflammation or autoimmune disorders. Although they hold great promise in the treatment of immune disorders such as graft versus host disease (GvHD) and allergic disorders, there remain many challenges to overcome before their widespread clinical application. An understanding of the biological properties of MSCs will clarify the mechanisms of MSC-based transplantation for immunomodulation. In this review, we summarize the preclinical and clinical studies of MSCs from different adult tissues, discuss the current hurdles to their use and propose the future development of pluripotent stem cell-derived MSCs as an approach to immunomodulation therapy.

Identifiers

Citations and references

Cited by 20 references